Time-Restricted Eating in Huntington’s Disease: Review of the Literature and a Proposed Clinical Trial
Objective: Review recent literature on time-restricted eating (TRE) in Huntington’s disease (HD) and outline our protocol for an upcoming clinical trial designed to assess the…Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson’s Disease: A Longitudinal, Multi-Sensory Intervention Study
Objective: This study aims to explore the neuroprotective effects of controlled diurnal light exposure on neurodegeneration rates in early-stage PD patients, positing that light therapy…Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Experience
Objective: To report on the selection of an imaging biomarker for a sub-study in a multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in…Therapeutic restoration of Faecalibacterium prausnitzii in Parkinson’s disease using targeted fructoligosaccharides: a double-blind, placebo-controlled, cross-over trial
Objective: In this study, we evaluated the effect of targeted fructoligosaccharide (FOS) therapy to restore the beneficial butyrate producer Faecalibacterium prausnitzii, one the most highly reduced…Design, synthesis and pharmacological evaluation of 16-pyridylmethylene derivatives of steroidal oximes as antiparkinsonian agents in MPTP-injected mice.
Objective: The objective of the present study is focused on the design and synthesis of 16-pyridyl methylene derivatives of steroidal oximes and further their pharmacological…Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models
Objective: This study investigates the potential neuroprotective effects of several mushroom extracts in PD in-vitro models. Background: Parkinson's disease, a progressive condition, involves dysfunction or…TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.
Objective: To assess efficacy and potency of our proprietary lead compound OT-003, an orally bioavailable small molecule Tropomyosin receptor kinase B (TrkB) modulator, in preclinical…Quercetin hinders Glial Activation to Alleviate the Cadmium Induced Dopaminergic Alteration via TNFα mediated CAMKIIα/ERK activation
Objective: The present study has therefore been carried out identify neuroprotective role of quercetin in alleviating the cadmium induced dopaminergic dysfunctions via glial mediated deactivation…Effects of a small molecule angiotensin IV analog on Huntington’s disease animal model
Objective: The present study was designed to test if N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide (AngIV-6a), an angiotensin IV analog, could attenuate 3-nitropropionic acid-induced Huntington’s disease-like symptoms in…Pharmacological Invivo and invitro potential of resveratrol in experimental rat models of Parkinson’s disease
Objective: Aim of study was to elucidate the pharmacological Invivo and invitro effects and mechanisms of action ofRT in experimental models of PD. Background: The…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 15
- Next Page »